Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 19/20 | 0.55 |
| ▸ | CA2 | P00918 | 19/20 | 0.55 |
| ▸ | CA9 | Q16790 | 10/20 | 0.55 |
| ▸ | CA12 | O43570 | 9/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 8/20 | 0.55 |
| ▸ | CA4 | P22748 | 4/20 | 0.49 |
| ▸ | CA3 | P07451 | 2/20 | 0.44 |
| ▸ | CA6 | P23280 | 2/20 | 0.44 |
| ▸ | CA5A | P35218 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.44 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6845362 | 0.91 | CA1 (0.42) | CA1CA2CA9CA12CA14 | |
| SCHEMBL6843386 | 0.90 | CA1 (0.41) | CA1CA2CA9CA12CA14 | |
| SCHEMBL6843439 | 0.88 | CA2 (0.48) | CA1CA2CA9CA12CA14 | |
| SCHEMBL6843115 | 0.87 | ALDH1A1 (0.52) | CA1CA2CA9CA12CA14 | |
| SCHEMBL6194312 | 0.86 | MAPT (0.50) | — | |
| SCHEMBL6843051 | 0.85 | MAPT (0.49) | CYP2C19 | |
| SCHEMBL6844635 | 0.85 | RXRA (0.46) | — | |
| SCHEMBL6844741 | 0.85 | NR4A2 (0.46) | CYP2C19 | |
| SCHEMBL6845387 | 0.85 | RXRA (0.46) | — | |
| SCHEMBL6843419 | 0.85 | RXRA (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040043983-A1 | Naphthalene derivatives as matrix metalloproteinase inhibitors | LI JIE JACK (US) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043983-A1 | Naphthalene derivatives as matrix metalloproteinase inhibitors | MMP9, MMP8, MMP13 | CA1 2024/4885CA2 982/4885CA9 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.